Go to the briefing

First, name what is on offer

A visit, a drug, a claim: keep them apart.

What did the page offer you: time with a clinician, a named medicine, or a substance sent by post? Start there. Those are different things to check.

Begin · a learning step

Check the visit and the product

You can discuss a health concern at an online visit. Write down what you want assessed before looking at a treatment menu.

A patient’s menu choice cannot be the sole basis for prescribing under medical-board guidance reviewed in September 2026.

Note A

These are recommendations to state medical boards. Each state decides which rules apply to your visit.

Ask how the person will review your concern and what else they need to know.

The product needs its own check

The name peptide describes tiny chemical parts forming a short chain. Picture a row of beads threaded together. Insulin belongs to this group of substances.

The label peptide could not establish a product’s safety or legal status in September 2026.

Note B

Ask what kind of product is offered: does the medicine have approval, is it prepared to order, or does its label describe research use rather than treating people? Get the exact name and how it would be given in writing. Ask what any research label means before agreeing to use the product in your care.

Read the drug-name briefing

Made to order does not mean reviewed

Compounding involves preparing or mixing the medicine to fill an order. The alternative is supplying a finished product made in a factory.

Compounded medicines lacked FDA approval in September 2026.

Note C

The Food and Drug Administration reviews drugs at the federal level; FDA is its short name.

Before paying, ask why that exact preparation is being proposed for your concern.

Page notes

  1. Medical-board guidance on treatment menus

    This guidance calls for assessment and a chance to ask the clinician follow-up questions.

    Back to the briefing
  2. FDA explanation of pharmacy-made drugs

    The way a visit takes place does not settle which rules apply to the drug being offered.

    Back to the briefing
  3. FDA account of what it does not review

    The review gap applies to a compounded product even when a pharmacy is well run.

    Back to the briefing